Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 172,561	$ 141,666
Accounts receivable	30,093	96,043
Inventories	16,325	15,161
Deferred tax assets, net	1,264	1,264
Income tax receivable, net	588	0
Prepaid expenses and other current assets	13,184	9,213
Total current assets	234,015	263,347
Property, plant and equipment, net	263,056	241,764
In process research and development	41,800	41,800
Goodwill	14,294	5,502
Intangible assets, net	30,771	0
Deferred tax assets, net	11,087	11,087
Other assets	441	730
Total assets	595,464	564,230
Current liabilities:
Accounts payable	29,018	31,297
Accrued expenses and other current liabilities	1,359	1,603
Accrued compensation	18,421	22,726
Contingent purchase consideration, current portion	1,326	0
Long-term indebtedness, current portion	4,470	4,470
Deferred revenue	2,038	1,811
Total current liabilities	56,632	61,907
Contingent purchase consideration, net of current portion	15,255	0
Long-term indebtedness, net of current portion	54,952	58,304
Other liabilities	1,768	1,891
Total liabilities	128,607	122,102
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 36,714,299 shares issued and 36,311,141 shares outstanding at September 30, 2013; 36,272,550 shares issued and 35,869,392 shares outstanding at December 31, 2012	37	36
Additional paid-in capital	240,372	230,964
Treasury stock, at cost, 403,158 common shares at September 30, 2013 and December 31, 2012	(5,906)	(5,906)
Accumulated other comprehensive loss	(3,502)	(4,129)
Retained earnings	236,305	220,393
Total Emergent BioSolutions Inc. stockholders' equity	467,306	441,358
Noncontrolling interest in subsidiaries	(449)	770
Total stockholders' equity	466,857	442,128
Total liabilities and stockholders' equity	$ 595,464	$ 564,230